Carisma Therapeutics, Inc. (CARM) Financial Ratios
14 years of historical data (2011–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low2.6·High2.6
P/FCF
N/A
—
5yr avg: N/A
30Y Low15.8·High15.8
P/B Ratio
↑
N/A
—
5yr avg: 2.28
30Y Low0.9·High4.7
ROE
↓
N/A
—
5yr avg: -249.8%
30Y Low-481%·High7%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
CARM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Carisma Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $795056 | $17M | $98M | $491M | $149M | $160M | $95M | $88M | $21M | $42M | $57M |
| Enterprise Value | $-14632944 | $2M | $24M | $507M | $-14045200 | $104M | $46M | $37M | $6M | $16M | $35M |
| P/E Ratio → | -0.01 | — | — | — | — | — | — | — | — | 21.95 | — |
| P/S Ratio | 0.04 | 0.88 | 6.58 | 49.90 | 5.60 | 14.20 | — | — | 49.80 | 1.38 | 57.75 |
| P/B Ratio | — | — | 3.70 | — | 0.87 | — | — | 1.98 | 1.17 | 1.07 | 3.02 |
| P/FCF | — | — | — | — | — | — | — | — | — | 15.84 | — |
| P/OCF | — | — | — | — | — | — | — | — | — | 15.84 | — |
P/E links to full P/E history page with 30-year chart
CARM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.10 | 1.59 | 51.52 | -0.53 | 9.27 | — | — | 15.26 | 0.54 | 35.34 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | 2.55 | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | 7.55 | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | 6.17 | — |
CARM Profitability
Margins and return-on-capital ratios measuring operating efficiency
Carisma Therapeutics, Inc. earns an operating margin of -316.7%. Operating margins have expanded from -571.1% to -316.7% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -204.0% | -204.0% | -396.8% | 100.0% | 99.7% | 100.0% | — | — | 100.0% | 100.0% | 100.0% |
| Operating Margin | -316.7% | -316.7% | -594.8% | -571.1% | -106.1% | -252.6% | — | — | -4702.4% | 20.6% | -3555.2% |
| Net Profit Margin | -308.1% | -308.1% | -582.3% | -622.6% | -1.3% | -252.3% | — | — | -6830.4% | 6.3% | -3379.0% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -327.4% | -421.7% | -0.4% | — | -1228.1% | -108.3% | -102.4% | 6.6% | -120.0% |
| ROA | -100.8% | -100.8% | -107.5% | -31.8% | -0.1% | -18.7% | -95.2% | -36.1% | -32.4% | 2.7% | -72.9% |
| ROIC | — | — | — | — | -232.8% | — | — | — | -179.6% | 91.6% | — |
| ROCE | -141.2% | -141.2% | -140.7% | -31.8% | -11.9% | -20.5% | -34.9% | -29.2% | -23.4% | 9.5% | -89.1% |
CARM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $18M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.12 | — | — | — | — | — | — | — | 0.73 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -2.81 | — | -0.95 | — | — | -1.14 | -0.81 | -0.66 | -1.17 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | -3.99 | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | -9.67 | — |
| Interest Coverage | — | — | — | -18.47 | — | — | — | — | — | 8.68 | -22.98 |
Net cash position: cash ($18M) exceeds total debt ($2M)
CARM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.48x means Carisma Therapeutics, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.78x to 1.48x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.48 | 1.48 | 5.06 | 2.78 | 17.77 | 3.48 | 6.39 | 8.47 | 3.17 | 6.51 | 4.79 |
| Quick Ratio | 1.48 | 1.48 | 5.06 | 2.78 | 17.77 | 3.48 | 6.39 | 8.47 | 3.17 | 6.51 | 4.79 |
| Cash Ratio | 1.17 | 1.17 | 4.88 | 2.64 | 14.06 | 3.07 | 5.65 | 8.25 | 3.11 | 6.37 | 4.76 |
| Asset Turnover | — | 0.64 | 0.17 | 0.14 | 0.08 | 0.06 | — | — | 0.01 | 0.29 | 0.03 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 53.25 | — | — | 336.80 | — | — | — | — | — | — |
CARM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Carisma Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | 4.6% | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | 6.3% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $41M | $34M | $40M | $9M | $6M | $5M | $3M | $1M | $1M | $949650 |
Peer Comparison
Compare CARM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 CARMYou | $795056 | -0.0 | — | — | -204.0% | -316.7% | — | — | — |
 MGTX | $1B | -8.0 | — | — | 94.0% | -130.2% | -368.2% | -241.1% | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 SANA | $877M | -3.3 | — | — | — | — | -118.7% | -74.4% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 KYMR | $7B | -24.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ALNY | $37B | 119.4 | 65.9 | 79.7 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 EDIT | $263M | -1.5 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.2% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
CARM — Frequently Asked Questions
Quick answers to the most common questions about buying CARM stock.
What is Carisma Therapeutics, Inc.'s P/E ratio?
Carisma Therapeutics, Inc.'s current P/E ratio is -0.0x. The historical average is 22.0x.
Is CARM stock overvalued?
Based on historical data, Carisma Therapeutics, Inc. is trading at a P/E of -0.0x. Compare with industry peers and growth rates for a complete picture.
What are Carisma Therapeutics, Inc.'s profit margins?
Carisma Therapeutics, Inc. has -204.0% gross margin and -316.7% operating margin.